125 related articles for article (PubMed ID: 11961344)
1. Effect of the somatostatin analogue lanreotide on meal-stimulated portal blood flow in patients with liver cirrhosis.
Schiedermaier P; Harrison P; Arthur M; Grandt D; Sutton R; Drewe J; Larsen F; Sieber C;
Digestion; 2002; 65(1):56-60. PubMed ID: 11961344
[TBL] [Abstract][Full Text] [Related]
2. Lanreotide effect on splanchnic blood flow in healthy subjects: effect of the rate of infusion.
Sieber CC; Beglinger C; Bart S; Tschoepl M; Currie G; Larsen F; Drewe J
Clin Pharmacol Ther; 2004 Jan; 75(1):70-9. PubMed ID: 14749693
[TBL] [Abstract][Full Text] [Related]
3. Hemodynamic effects of the somatostatin analog lanreotide in humans: placebo-controlled, cross-over dose-ranging Echo-Doppler study.
Mottet C; Sieber CC; Nauer A; Drewe J; Fried R; Larsen F; Beglinger C
Hepatology; 1998 Apr; 27(4):920-5. PubMed ID: 9537429
[TBL] [Abstract][Full Text] [Related]
4. Effect of propranolol and depot lanreotide SR on postprandial and circadian portal haemodynamics in cirrhosis.
Schiedermaier P; Koch L; Stoffel-Wagner B; Layer G; Sauerbruch T
Aliment Pharmacol Ther; 2003 Oct; 18(8):777-84. PubMed ID: 14535870
[TBL] [Abstract][Full Text] [Related]
5. Effect of somatostatin on splanchnic hemodynamics in patients with liver cirrhosis and portal hypertension.
Merkel C; Gatta A; Zuin R; Finucci GF; Nosadini R; Ruol A
Digestion; 1985; 32(2):92-8. PubMed ID: 2864299
[TBL] [Abstract][Full Text] [Related]
6. Postprandial splanchnic haemodynamic changes in patients with liver cirrhosis and patent paraumbilical vein.
Berzigotti A; Dapporto S; Angeloni L; Ramilli S; Bianchi G; Morelli MC; Magalotti D; Zoli M
Eur J Gastroenterol Hepatol; 2004 Nov; 16(12):1339-45. PubMed ID: 15618843
[TBL] [Abstract][Full Text] [Related]
7. Effects of lanreotide, a somatostatin analogue, on postprandial gastric functions and biliopancreatic secretions in humans.
Lamrani A; Vidon N; Sogni P; Nepveux P; Catus F; Blumberg J; Chaussade S
Br J Clin Pharmacol; 1997 Jan; 43(1):65-70. PubMed ID: 9056054
[TBL] [Abstract][Full Text] [Related]
8. Dose-dependent gastrointestinal effects of the somatostatin analog lanreotide in healthy volunteers.
Drewe J; Sieber CC; Mottet C; Wullschleger C; Larsen F; Beglinger C
Clin Pharmacol Ther; 1999 Apr; 65(4):413-9. PubMed ID: 10223779
[TBL] [Abstract][Full Text] [Related]
9. Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension.
Albillos A; Rossi I; Iborra J; Lledó JL; Calleja JL; Barrios C; García P; Escartín P
J Hepatol; 1994 Jul; 21(1):88-94. PubMed ID: 7963427
[TBL] [Abstract][Full Text] [Related]
10. Octreotide inhibits the meal-induced increases in the portal venous pressure of cirrhotic patients with portal hypertension: a double-blind, placebo-controlled study.
McCormick PA; Biagini MR; Dick R; Greenslade L; Chin J; Cardin F; Wagstaff D; McIntyre N; Burroughs AK
Hepatology; 1992 Nov; 16(5):1180-6. PubMed ID: 1427656
[TBL] [Abstract][Full Text] [Related]
11. [Splanchnic hemodynamic effects of somatostatin and octreotide in cirrhotic patients. A Doppler ultrasonographic study].
Fernández Pérez FJ; Jiménez Sáenz M; García Montes JM; Rebollo Bernárdez J; Herrerías Gutiérrez JM
Rev Esp Enferm Dig; 2008 Sep; 100(9):552-9. PubMed ID: 19025306
[TBL] [Abstract][Full Text] [Related]
12. Postmeal portal flow variations in HCV-related chronic hepatitis and liver cirrhosis with and without hyperdynamic syndrome.
Zardi EM; Dobrina A; Uwechie V; Cacciapaglia F; Rollo M; Laghi V; Ambrosino G; Lumachi F
In Vivo; 2008; 22(4):509-12. PubMed ID: 18712180
[TBL] [Abstract][Full Text] [Related]
13. Lanreotide on collateral response to endothelin-1 and vasopressin in cirrhotic rats.
Huang HC; Wang SS; Lee FY; Chang FY; Lin HC; Hou MC; Yang YY; Lee SD
J Chin Med Assoc; 2006 Sep; 69(9):397-403. PubMed ID: 17051749
[TBL] [Abstract][Full Text] [Related]
14. Effects of somatostatin, terlipressin and somatostatin plus terlipressin on portal and systemic hemodynamics and renal sodium excretion in patients with cirrhosis.
Kalambokis G; Economou M; Paraskevi K; Konstantinos P; Pappas C; Katsaraki A; Tsianos EV
J Gastroenterol Hepatol; 2005 Jul; 20(7):1075-81. PubMed ID: 15955217
[TBL] [Abstract][Full Text] [Related]
15. 48-hour hemodynamic effects of octreotide on postprandial splanchnic hyperemia in patients with liver cirrhosis and portal hypertension: double-blind, placebo-controlled study.
Ludwig D; Schädel S; Brüning A; Schiefer B; Stange EF
Dig Dis Sci; 2000 May; 45(5):1019-27. PubMed ID: 10795771
[TBL] [Abstract][Full Text] [Related]
16. Influence of esophageal varices and spontaneous portal-systemic shunts on postprandial splanchnic hemodynamics.
Siringo S; Piscaglia F; Zironi G; Sofia S; Gaiani S; Zammataro M; Bolondi L
Am J Gastroenterol; 2001 Feb; 96(2):550-6. PubMed ID: 11232705
[TBL] [Abstract][Full Text] [Related]
17. The postprandial portal flow is related to the severity of portal hypertension and liver cirrhosis.
Ludwig D; Schwarting K; Korbel CM; Brüning A; Schiefer B; Stange EF
J Hepatol; 1998 Apr; 28(4):631-8. PubMed ID: 9566832
[TBL] [Abstract][Full Text] [Related]
18. Upright posture blunts postprandial splanchnic hyperemia in patients with cirrhosis and portal hypertension.
Iwao T; Oho K; Nakano R; Yamawaki M; Sakai T; Sato M; Miyamoto Y; Sakai K; Sata M; Toyonaga A
J Gastroenterol; 1999 Jun; 34(3):359-65. PubMed ID: 10433012
[TBL] [Abstract][Full Text] [Related]
19. Long-term haemodynamic effects of octreotide on postprandial splanchnic hyperemia in humans: a placebo-controlled echo-doppler study.
Ludwig D; Terai S; Brüning A; Stange EF
Aliment Pharmacol Ther; 1999 Aug; 13(8):1119-29. PubMed ID: 10468691
[TBL] [Abstract][Full Text] [Related]
20. A randomized study of propranolol on postprandial portal hyperemia in cirrhotic patients.
Sabbá C; Ferraioli G; Buonamico P; Mahl T; Taylor KJ; Lerner E; Albano O; Groszmann RJ
Gastroenterology; 1992 Mar; 102(3):1009-16. PubMed ID: 1537492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
